For Physicians

If you have patients with hypoparathyroidism who are looking for options, you may want to consider referring them to the BALANCE clinical research study.

The BALANCE study is evaluating whether adding an investigational medication called recombinant human parathyroid hormone (rhPTH[1-84]) to standard hypoparathyroidism therapy (oral calcium and active vitamin D tablets) may help control the symptoms of hypoparathyroidism better than standard therapy alone.

A patient may be eligible for the study if he or she:

  • Is between 18 and 85 years of age
  • Has had hypoparathyroidism for at least 12 months
  • Has two or more symptoms related to hypoparathyroidism

Do you have a patient who may be eligible for the BALANCE study?

For additional information about this study and how to refer a patient, please provide your contact information below. You will be contacted by a study representative soon. Thank you for your consideration.